Melanoma Insights for Professionals

Mucosal melanoma is a rare and aggressive form of melanoma that arises from the mucous membrane. In this podcast, we focus on mucosal melanoma of the head and neck. Led by A/Prof Sydney Ch’ng, our multidisciplinary experts discuss how it differs from cutaneous melanoma, staging of mucosal melanoma, management of the disease and future treatments. The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Plastic Surgeons, Surgical Oncologists, Dermatologists, Medical Oncologists, Pathologists, GPs, Nurses and other healthcare professionals. Register now to attend the 2024 Australasian Melanoma Conference, hosted by Melanoma Institute Australia. SPEAKERS A/Prof Sydney Ch’ng Prof Georgina Long AOA/Prof Raewyn CampbellDr Robert RawsonProf Angela Hong Please note that this podcast was accurate at the time of recording (March 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS and HEINE.

Diagnostic uncertainty in the context of cutaneous melanoma can have significant impact on patient care. In this podcast, our multidisciplinary experts, led by Dr Adrian Quek, discuss the challenges faced in classifying melanocytic lesions that fall into a diagnostic grey area, and explore the terminology, evolving classifications and the impact of diagnostic uncertainty on patient outcomes. From molecular changes to clinical perspectives, this engaging discussion provides a comprehensive exploration of the complexities surrounding borderline lesions, and emphasises the need for experienced multidisciplinary professionals in ensuring accurate diagnoses and ideal management. This podcast is suitable for Pathologists, Dermatologists, Surgeons, Oncologists, GPs and other healthcare professionals. Register now to attend the ⁠2024 Australasian Melanoma Conference⁠, hosted by Melanoma Institute Australia. RESOURCES How to diagnose borderline cutaneous melanocytic lesions New and evolving concepts of melanocytic nevi and melanocytomas. Modern Pathology Nevus/Melanocytoma/Melanoma: An Emerging Paradigm for Classification of Melanocytic Neoplasms?Arch Pathol Lab Med SPEAKERS Dr Adrian Quek - A/Prof Robyn Saw - Prof H. Peter SoyerDr Andrew Colebatch Please note that this podcast was accurate at the time of recording (November 2023) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE. For more clinical education from MIA, sign up to the Melanoma Education Portal.

With the advent of effective medical therapies for melanoma, a pertinent question has arisen: When should we scan our patients? In this podcast, our multidisciplinary experts, led by A/Prof Sydney Ch’ng, discuss the balance of whether we should be more aggressive in our pursuit of identifying potential metastases or exercise caution to avoid unnecessary scans, radiation exposure and patient anxiety. The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Medical Oncologists, Oncologists, Surgeons, GPs, Oncology Nurses and other healthcare professionals. RESOURCES Melanoma Risk Prediction Tools SPEAKERS A/Prof Sydney Ch’ng - A/Prof Alexander Menzies - A/Prof Alexander van Akkooi - Dr Edward Hsiao - Dr Kevin London - Please note that this podcast was accurate at the time of recording (September 2023) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. For more practice-changing education, visit our Melanoma Education Portal. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Sentinel node biopsy (SNB) plays a key role in assessing the prognosis of melanomas. In this fireside chat from our new SNB Training Program (Sentinel Node Biopsy: From guidelines to practice), MIA’s Prof Georgina Long AO, Prof John Thompson AO and A/Prof Sydney Ch’ng discuss: This podcast is suitable for Surgeons, Medical Oncologists, General Practitioners and other healthcare professionals. SPEAKERS Please note that this podcast was accurate at the time of recording (July 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

Our latest podcast explores the innovative approach of neoadjuvant immunotherapy - administering checkpoint inhibitor immunotherapy before the surgical removal of melanoma. This promising approach is creating a buzz among multidisciplinary clinicians and researchers globally as the potential benefits for melanoma patients are being realised. Although neoadjuvant therapy is well established in oncology, using immunotherapy in melanoma has revolutionised patient outcomes through significant improvements in overall survival rates. In this engaging podcast, MIA’s Prof Georgina Long AO leads a discussion with multidisciplinary world leaders in the neoadjuvant space to discuss: The discussion concludes with case studies to summarise key learnings. This podcast is suitable for Medical Oncologists, Oncologists, Surgeons, Pathologists, Dermatologists, GPs, Oncology Nurses and other healthcare professionals. SPEAKERS: Prof Georgina Long AO - Prof Richard Scolyer AO - A/Prof Alexander Menzies - A/Prof Alexander van Akkooi KEY CLINICAL TRIALS SWOGPRADOOpACIN-neoNADINA FURTHER EDUCATION The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists Please note that this podcast was accurate at the time of recording (February 2023) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Lentigo maligna – a subtype of in situ melanoma – presents diagnostic and treatment challenges for clinicians. In this podcast, Dr Michael Rtshiladze leads a multidisciplinary discussion to unravel our understanding of the pathology, diagnosis and management of lentigo maligna, including: The discussion concludes with a case study to summarise key learnings. This podcast is suitable for Plastic Surgeons, General Surgeons, Dermatologists, Oncologists, Pathologists, GPs, Nurses and other healthcare professionals. SPEAKERS Dr Michael RtshiladzeDr Robert RawsonProf Pascale GuiteraProf Angela Hong RESOURCE AND REFERENCE Lentigo Maligna Patient Information BrochureClinical outcomes following surgical treatment of lentigo maligna of the head and neck.Eur J Surg Oncol. Please note that this podcast was accurate at the time of recording (December 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

Despite recent advances in management of primary uveal melanoma, more than half of patients develop metastatic disease – often with poor outcomes. New therapeutic approaches to metastatic disease are vital. In this podcast, A/Prof Matteo Carlino interviews fellow Medical Oncologist Prof Georgina Long AO and Ophthalmologist A/Prof Max Conway on our latest understanding of the diagnosis and management of early and advanced uveal melanoma, including: This podcast is suitable for Oncologists, Ophthalmologists, GPs, Oncology Nurses and other healthcare professionals. SPEAKERS A/Prof Matteo CarlinoProf Georgina Long AOA/Prof Max Conway RESOURCES Early Ocular Melanoma Patient Information BrochureAdvanced Ocular Melanoma Patient Information BrochureMelanoma Education Portal Please note that this podcast was accurate at the time of recording (November 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, BMS, Novartis and HEINE.

Treating clinicians rely on pathology to help diagnose and stage their patient which fundamentally determines the treatment management plan. Therefore, it is incredibly important to get it right in the first place. In this engaging podcast aimed at GPs, our multidisciplinary experts discuss: The discussion is concluded with two case studies to summarise key learnings. This podcast is suitable for GPs, Dermatologists, Surgeons, Oncologists, Pathologists and other healthcare professionals. SPEAKERS Dr Adrian QuekDr Alison PotterDr Nigel MaherA/Prof Alexander van AkkooiDr Niamh-Anna O’Sullivan HOST Danielle Fischer Please note that this podcast was accurate at the time of recording (June 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. For more practice-changing education, visit our Melanoma Education Portal. MIA's Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

The role of pathology in the diagnosis and treatment of melanoma is pivotal to optimal patient care. With so many disciplines relying on the pathologist for accurate diagnoses and critical pathological information, we decided to reach out to our clinical melanoma community to ask them for their critical pathology questions. In this podcast, Prof John Thompson AO and Prof Fergal Moloney pick at the brain of the world's leading melanoma Pathologist, Prof Richard Scolyer AO, as they discuss: This podcast is suitable for GPs, Dermatologists, Surgeons, Oncologists, Pathologists and other healthcare professionals. SPEAKERS Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney Prof John Thompson AO - Emeritus Professor of Melanoma and Surgical Oncology, The University of Sydney | Member, Melanoma Institute Australia Prof Fergal Moloney - Consultant Dermatologist, Melanoma Institute Australia and Mater Misericordiae University Hospital | Clinical Professor, University College, Dublin Please note that this podcast was accurate at the time of recording (June 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. For more practice-changing education, visit our Melanoma Education Portal. MIA's Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

Cancer drugs have rapidly evolved in the last decade. Alongside the significant benefits are new toxicity profiles that clinicians need to be aware of and manage. In this podcast, A/Prof Carlino interviews fellow Medical Oncologist Prof Georgina Long AO on the adverse events/toxicities associated with targeted therapies (combination BRAF/MEK inhibitors) and immunotherapies (anti-PD-1, anti-LAG-3 and anti-CTLA-4), particularly in melanoma, and how they should be managed. This podcast is suitable for Oncologists, Emergency Medicine Physicians, GPs, Oncology Nurses and other healthcare professionals. SPEAKERS Prof Georgina Long AOA/Prof Matteo Carlino Please note that this podcast was accurate at the time of recording (May 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. MIA’s Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb, Novartis and HEINE.

The field of melanoma has experienced a paradigm shift in recent years, with advancements in both diagnosis and management driving improved patient outcomes. Through the power of research, day-to-day practice continues to be transformed. In this lively podcast, two of Australia's leading melanoma experts Prof Richard Scolyer AO and Prof Georgina Long AO discuss: In this practical discussion, resources and further education for deeper dives into specific topics are also mentioned, with links below. This podcast is suitable for oncologists, surgeons, dermatologists, skin cancer GPs, GPs, nurses and other healthcare professionals. SPEAKERS Prof Georgina Long AOProf Richard Scolyer AO LINKS TO RESOURCES Melanoma Risk Prediction Tools Update on melanoma staging Melanoma Staging Card Melanoma near misses: Clues to diagnosis Techniques in melanoma assessmentDermChallenge: ManagementTo shave or not to shave when biopsying melanomaMultidisciplinary management of primary melanomaThe melanoma pathology report and its impact on clinical management Clinical practice guidelines for the diagnosis and management of melanomaThe current role of sentinel node biopsy in the management of melanoma SNB Melanoma Risk Calculator Visit the Melanoma Education Portal for the full list of resources.

Managing in-transit melanoma can be challenging, and it presents and progresses as a heterogeneous disease. Multidisciplinary care is recommended for this complex disease to determine the optimal outcome for the patient. In this engaging podcast, our multidisciplinary expert panel - featuring a Dermatologist, Surgeon and Medical Oncologist - discuss: In addition, the panel reviews a case study to put learnings into practice. This podcast is suitable for Surgeons, Medical Oncologists, Dermatologists, Skin Cancer GPs, GPs, Nurses and other healthcare professionals. Please note that this podcast was accurate at the time of recording (October 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. SPEAKERS A/Prof Matteo Carlino A/Prof Robyn SawProf Diona Damian

Melanoma has many mimics, making detection a challenge. However, early detection and appropriate management of melanoma is crucial to ensuring a patient has the best chance of survival.

Due to the highly aggressive nature of Merkel cell carcinoma, accurate and timely diagnosis is essential to ensure optimal management. Although our understanding of the biology of the disease has advanced significantly in recent years, a clinical conundrum still exists regarding the ideal therapeutic strategy for each patient. In this podcast, our multidisciplinary panel discuss: In addition, the panel reviews two case studies to put learnings into practice. This podcast is suitable for Medical Oncologists, Surgeons, Dermatologists, GPs, Nurses and other healthcare professionals. Please note that this podcast was accurate at the time of recording (March 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. SPEAKERS: Dr Robert RawsonDr Kerwin ShannonProf Angela HongDr Ines Silva

Hear our expert multidisciplinary panel discuss the latest management options for the treatment of squamous cell carcinoma and basal cell carcinoma - the most common forms of non-melanoma skin cancers. They have a wide clinical and pathological presentation, and early detection and treatment is vital to reduce the morbidity and mortality associated with these diseases. In this podcast, our multidisciplinary panel discuss: In addition, the panel review two cases to solidify the learnings. This podcast is suitable for Medical Oncologists, Surgeons, Dermatologists, GPs, Nurses and other healthcare professionals. Please note that this podcast was accurate at the time of recording (March 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. SPEAKERS: Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital Dr Kerwin Shannon - Surgical Oncologist and Head and Neck Surgeon, Melanoma Institute Australia and Chris O’Brien Lifehouse Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia |Clinical Professor, The University of Sydney Dr Ines Silva - Medical Oncologist and Researcher, Melanoma Institute Australia | Fellow, Westmead Hospital

The success of immunotherapy and targeted therapy in the treatment of advanced melanoma has led to the same therapies being used in the adjuvant setting to reduce the risk of recurrence. In this podcast, A/Prof Matteo Carlino interviews fellow Medical Oncologist A/Prof Alexander Menzies on the evidence for adjuvant therapy to guide clinical decision-making. Understanding the complexities of adjuvant therapy is key to identifying and managing patients suitable for this treatment. Topics covered in this discussion include: This podcast is suitable for Oncologists, Oncology Nurses and other healthcare professionals. Please note that this podcast was accurate at the time of recording (Feb 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. SPEAKERS: A/Prof Alexander MenziesA/Prof Matteo Carlino

In the rapidly evolving treatment landscape for advanced melanoma, medical oncologists now have a suite of treatments to choose from for their patients. In this engaging podcast, A/Prof Menzies interviews fellow Medical Oncologist A/Prof Carlino on the rationale behind their clinical decision making when it comes to choosing the most appropriate therapy for their patients, including sequencing and combination therapies. They also take a deeper dive into treatment toxicities and how to manage them for targeted and immune therapies. This podcast is suitable for Oncologists, Oncology Nurses and other healthcare professionals. Please note that this podcast was accurate at the time of recording (June 2020) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

Melanoma is one of the most common human malignancies, however we often don't often think of it as a disease that occurs in children. Although exceedingly rare, clinicians do need to be aware of paediatric melanoma and have a high level of suspicion for these lesions as they are often diagnosed late. In this podcast, a Surgeon, Dermatologist and Medical Oncologist discuss how melanoma presents in children and adolescents, and how this differs from the adult setting. They also discuss how melanoma should be managed in these patients and discuss two patient case studies. This podcast is suitable for Surgeons, Dermatologists, Medical Oncologists, GPs and other healthcare professionals. SPEAKERS A/Prof Matteo CarlinoDr Gideon Sandler - Dr Li-Chuen Wong

In the evolving treatment landscape of melanoma, it is important for GPs and Dermatologists to be confident in managing or knowing when to refer their melanoma patients. In this podcast, Surgeon A/Prof Robyn Saw, Dermatologist Dr Annika Smith and Skin Cancer GP Dr Adrian Quek discuss the ideal biopsy for a melanoma diagnosis, provides an overview of management of early stage disease, outlines the role of sentinel lymph node biopsy and discusses which patients need referral to a specialist melanoma clinic.

In the last decade, the treatment landscape for melanoma has been transformative for patients with advanced disease. Although managed primarily by medical oncologists, it is important for GPs to be across which treatments are available for their patients as they are often the first point of contact when a patient becomes unwell. In this podcast, Medical Oncologist Professor Georgina Long discusses how systemic therapy is used in the treatment of advanced melanoma, and how a GP can identify and manage toxicities in patients being treated with targeted or immunotherapies. This podcast is suitable for GPs, Skin Cancer GPs, nurses and other healthcare professionals. Please note that this podcast was accurate at the time of recording (Oct 2019) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.